selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 ex...

Related Keywords

Germany ,Martinsried ,Bayern ,San Diego ,California ,United States ,Munich ,Andreas Klostermann ,Steve Zaniboni ,Ludger Wess Ines Regina Buth ,Lion Inc ,Chief Scientific Officer ,Antonius Schuh ,Global Source ,Ludger Wess ,Ines Regina Buth ,